Press releases
- Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
- Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
More ▼
Key statistics
As of last trade Blueprint Medicines Corp (2L9:FRA) traded at 95.18, -6.69% below its 52-week high of 102.00, set on May 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 95.18 |
---|---|
High | 95.18 |
Low | 95.18 |
Bid | 95.64 |
Offer | 97.56 |
Previous close | 93.90 |
Average volume | 397.11 |
---|---|
Shares outstanding | 62.62m |
Free float | 62.06m |
P/E (TTM) | -- |
Market cap | 6.47bn USD |
EPS (TTM) | -4.82 USD |
Data delayed at least 15 minutes, as of Jun 11 2024 07:34 BST.
More ▼